Ethics and the Business of Biomedicine
Herausgeber: Arnold, Denis G.
Ethics and the Business of Biomedicine
Herausgeber: Arnold, Denis G.
- Gebundenes Buch
- Merkliste
- Auf die Merkliste
- Bewerten Bewerten
- Teilen
- Produkt teilen
- Produkterinnerung
- Produkterinnerung
Distinguished scholars of bioethics and business ethics discuss justice in relation to business-friendly strategies in the delivery of health care.
Andere Kunden interessierten sich auch für
- ElenaThe Power of Ethical Leadership Empowering Change in Business25,99 €
- Business Ethics and Care in Organizations194,99 €
- Institutional Integrity in Health Care110,99 €
- John W. DavisContemporary Issues in Biomedical Ethics38,99 €
- Scharmaine LawsonThe Business of Nur$ing Vol. 122,99 €
- Scharmaine LawsonThe Business of Nur$ing51,99 €
- William YeeThe Business of Medicine21,99 €
-
-
-
Distinguished scholars of bioethics and business ethics discuss justice in relation to business-friendly strategies in the delivery of health care.
Produktdetails
- Produktdetails
- Verlag: Cambridge University Press
- Seitenzahl: 302
- Erscheinungstermin: 11. Juni 2009
- Englisch
- Abmessung: 235mm x 157mm x 21mm
- Gewicht: 593g
- ISBN-13: 9780521764315
- ISBN-10: 0521764319
- Artikelnr.: 26055675
- Verlag: Cambridge University Press
- Seitenzahl: 302
- Erscheinungstermin: 11. Juni 2009
- Englisch
- Abmessung: 235mm x 157mm x 21mm
- Gewicht: 593g
- ISBN-13: 9780521764315
- ISBN-10: 0521764319
- Artikelnr.: 26055675
Introduction, 1. Medicine and the market Daniel Callahan; 2. Broken
promises: do business friendly strategies frustrate just health care?
Norman Daniels; 3. Are patents an efficient and internationally fair means
of funding research and development for new medicines? Paul Menzel; 4. The
exploitation of the economically disadvantaged in pharmaceutical research
disclosure Tom L. Beauchamp; 5. The dangers of detailing: how
pharmaceutical marketing threatens health care Jason Hubbard; 6. The ethics
of direct to consumer pharmaceutical advertising Denis G. Arnold; 7.
Industry-funded bioethics and the limits of disclosure Carl Elliott; 8. Two
cheers for the pharmaceutical industry Richard T. De George; 9. The third
face of medicine: ethics and business and challenges to professionalism
Mary V. Rorty, Patricia Werhane, and Ann Mills; 10. Theoretical foundations
for an organizational ethics: developing norms for a new kind of health
care George Khushf; 11. A crisis in medical professionalism: time for
Flexner II Daniel Wikler; Bibliography; Index.
promises: do business friendly strategies frustrate just health care?
Norman Daniels; 3. Are patents an efficient and internationally fair means
of funding research and development for new medicines? Paul Menzel; 4. The
exploitation of the economically disadvantaged in pharmaceutical research
disclosure Tom L. Beauchamp; 5. The dangers of detailing: how
pharmaceutical marketing threatens health care Jason Hubbard; 6. The ethics
of direct to consumer pharmaceutical advertising Denis G. Arnold; 7.
Industry-funded bioethics and the limits of disclosure Carl Elliott; 8. Two
cheers for the pharmaceutical industry Richard T. De George; 9. The third
face of medicine: ethics and business and challenges to professionalism
Mary V. Rorty, Patricia Werhane, and Ann Mills; 10. Theoretical foundations
for an organizational ethics: developing norms for a new kind of health
care George Khushf; 11. A crisis in medical professionalism: time for
Flexner II Daniel Wikler; Bibliography; Index.
Introduction, 1. Medicine and the market Daniel Callahan; 2. Broken
promises: do business friendly strategies frustrate just health care?
Norman Daniels; 3. Are patents an efficient and internationally fair means
of funding research and development for new medicines? Paul Menzel; 4. The
exploitation of the economically disadvantaged in pharmaceutical research
disclosure Tom L. Beauchamp; 5. The dangers of detailing: how
pharmaceutical marketing threatens health care Jason Hubbard; 6. The ethics
of direct to consumer pharmaceutical advertising Denis G. Arnold; 7.
Industry-funded bioethics and the limits of disclosure Carl Elliott; 8. Two
cheers for the pharmaceutical industry Richard T. De George; 9. The third
face of medicine: ethics and business and challenges to professionalism
Mary V. Rorty, Patricia Werhane, and Ann Mills; 10. Theoretical foundations
for an organizational ethics: developing norms for a new kind of health
care George Khushf; 11. A crisis in medical professionalism: time for
Flexner II Daniel Wikler; Bibliography; Index.
promises: do business friendly strategies frustrate just health care?
Norman Daniels; 3. Are patents an efficient and internationally fair means
of funding research and development for new medicines? Paul Menzel; 4. The
exploitation of the economically disadvantaged in pharmaceutical research
disclosure Tom L. Beauchamp; 5. The dangers of detailing: how
pharmaceutical marketing threatens health care Jason Hubbard; 6. The ethics
of direct to consumer pharmaceutical advertising Denis G. Arnold; 7.
Industry-funded bioethics and the limits of disclosure Carl Elliott; 8. Two
cheers for the pharmaceutical industry Richard T. De George; 9. The third
face of medicine: ethics and business and challenges to professionalism
Mary V. Rorty, Patricia Werhane, and Ann Mills; 10. Theoretical foundations
for an organizational ethics: developing norms for a new kind of health
care George Khushf; 11. A crisis in medical professionalism: time for
Flexner II Daniel Wikler; Bibliography; Index.